Skip to main content

Rosetta Inks Commercialization Deal for miRNA Tests with Genetic Technologies

Premium

Rosetta Genomics this week announced that it has signed an agreement making Australia's Genetic Technologies the exclusive distributor of its three miRview microRNA-based diagnostics in Australia, New Zealand, and Singapore.

Under the deal, Genetic Technologies will market Rosetta's miRview Meso, which differentiates lung cancer from mesothelioma; miRview Mets, which is designed to determine the source of cancers of unknown primary origin; and miRview Squamous, which is designed to differentiate squamous from non-squamous non-small cell lung cancer.

"This is an important first step in Genetic Technologies' move from predictive gene tests into advanced cancer management," Genetic Technologies CEO Paul MacLeman said in a statement.

Financial terms of the arrangement were not disclosed.

Rosetta's arrangement with Genetic Technologies comes a little more than a month after the miRNA shop licensed the Italian rights to the diagnostics to AXA Diagnostics (see RNAi News, 9/10/2009).

In August, Rosetta announced that it has licensed the rights to the diagnostics in India, Saudi Arabia, Qatar, and the United Arab Emirates to India’s Super Religare Laboratories (see RNAi News, 8/20/2009). That same month, Rosetta licensed the diagnostics’ Canadian market rights to Warnex Medical Laboratories (see RNAi News, 8/13/2009).

In April, Rosetta signed a deal giving Prometheus Laboratories the US rights to the three tests (see RNAi News, 4/16/2009). Prometheus has since launched the tests under its ProOnc line (see RNAi News, 10/15/2009).

In January, it licensed the Israeli and Turkish rights to Teva Pharmaceuticals (see RNAi News, 1/8/2009).

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.